Press Releases

Issuance of new shares in Mentice AB (publ) has been registered with the Swedish Companies Registration Office

Regarding the acquisition of the assets from Vascular Simulations Inc 571,974 shares have been issued at a subscription price of SEK 86.16 and regarding the acquisition of the assets from EQIP Inc, 9,469 shares have been issued at a subscription price of SEK 84.28

Mentice publishes the company’s interim report for the period July–September 2020

Two exciting acquisitions and strong performance in the medical device industry segmen

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2021

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2021 has been appointed

Mentice receives order of total SEK 6.1 million from Stryker

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has entered into an agreement with Stryker US to provide simulation solutions for its Neurovascular division

Mentice receives order of total SEK 7.1 million from ABBOTT

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has entered into an agreement with ABBOTT to provide simulation solutions for training of interventional devices

Mentice to acquire assets of health technology startup EQIP, Inc., adding technology for logging and analysis of clinical procedures

Mentice AB (publ) has today signed an agreement to acquire all substantial assets of EQIP, Inc. (EQIP), a startup medtech company based in Jacksonville, Florida. The purchase price amounts to 180 KUSD (approx. 1.6 MSEK) with a possible additional purchase price of maximum 70 KUSD (approx. 0.6 MSEK). Purchase price will be paid with a directed new shares issue in Mentice AB and cash payment

Mentice entered into an agreement to acquires all substantial assets of the US medical technology company Vascular Simulations Inc.

Mentice AB (publ), a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures acquires the substantial assets from Vascular Simulation Inc (Vascular Simulation). The purchase price amounts to 5.6 million USD (approx. 48 million SEK) with a possible additional purchase price of maximum 0.4 million USD (approx. 3.5 million SEK). Purchase price will be paid with a directed new shares issue in Mentice AB

Mentice engages Pareto Securities as liquidity provider

Mentice AB (publ), a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, engages Pareto Securities as liquidity provide

Mentice receives order of total SEK 5.5 million from BD (former Bard Peripheral Vascular)

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from BD (former Bard Peripheral Vascular) for the segment Medical Device Industry relating to solutions for physician training in the peripheral vascular area. The order covers system sales for a total order value of SEK 5.5 million and will be delivered during the third quarter 2020

Mentice publishes the company’s interim report for the period January–June 2020

Solid performance for the quarter and the first half of the year despite the effects of the pandemi

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on August 13 at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Mentice receives order of total SEK 7.0 million from Edwards Lifesciences

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Edwards Lifesciences for the segment Medical Device Industry relating to solutions for the Mitral/Tricuspid Valve therapy areas. The order covers system sales and development to be delivered during the fourth quarter 2020. The total order value amounts to SEK 7.0 million and will be accounted for in the order book for the third quarter 2020

Mentice receives order of total SEK 6.0 million from Abbott EP

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Abbott EP for the segment Medical Device Industry. The order covers system sales and development to be delivered during the third quarter 2020. The total order value amounts to SEK 6.0 million and will be accounted for in the order book for the second quarter 2020

Communique from annual general meeting in Mentice AB (publ)

Press release 2020-05-2

Mentice Launches Seventh Generation Platform to Help Transition Endovascular Therapy in a COVID-19 Era

VIST® G7 Introduces a Virtual Patient to Help Doctors Acquire, Retain, and Enhance Skills in the Absence of Procedural Volume.  

The Nomination Committee of Mentice AB has resolved to amend it previous proposition regarding Item 2 of the agenda for the Annual General Meeting to be held on May 27[th] 2020

The Nomination Committee of Mentice AB has resolved to amend it previous proposition regarding Item 2 of the agenda for the Annual General Meeting to be held on May 27th 2020 with regards to the proposed chairman of the meeting 202

Mentice publishes the company’s interim report for the period January–March 2020

Encouraging signs for the medium to long-term outlook, while the uncertainty in 2020 remain

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on May 14 at 10:00 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Annual shareholders’ meeting in Mentice AB

PRESS RELEAS

Mentice publishes the company’s year-end report for the period January–December 2019

Encouraging signs for 2020, despite continued lag in the medical device industry in Q

Mentice’s CEO Göran Malmberg to present the company’s year-end report 2019 at a webcast conference call on February 27 at 10:00 CET

Mentice AB (STO: MNTC) announces that the company will present its year-end report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Mentice publishes preliminary net sales and order intake figures for January–December 2019

Today, Mentice AB (STO: MNTC) publishes preliminary (unaudited) net sales and order intake figures for January–December 2019. The net sales figures are roughly in line with the revised full year forecast in the Q3 interim report, (with a 4-5% decrease in net sales), while order intake is 20% lower compared to last year. To address the current lag in order intake and improve overall sales performance, CEO Göran Malmberg is assuming direct responsibility for global sales activities